de Souza Maria das Graças C, Cyrino Fatima Z G A, Mayall Monica R, Virgini-Magalhães Carlos E, Sicuro Fernando L, de Carvalho Jorge José, Verbeuren Tony J, Bouskela Eliete
Laboratory for Clinical and Experimental Research on Vascular Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Department of Surgery, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Phlebology. 2016 Feb;31(1):50-6. doi: 10.1177/0268355514564414. Epub 2014 Dec 15.
To evaluate if the micronized purified flavonoid fraction (MPFF) treatment could reduce the side effects of sclerotherapy (a procedure frequently used to treat venous disease manifestations) by minimizing the inflammatory response within the surrounding tissues.
Twenty-two male New Zealand rabbits were treated by gavage with micronized purified flavonoid fraction (MPFF; 300 mg/kg/day) or vehicle (10% lactose solution) during 21 consecutive days, starting 7 days before sclerotherapy. The sclerotherapy consisted of an injection containing 5% ethanolamine oleate solution in the rabbit's dorsal ear vein. Before and after sclerotherapy, venular and arteriolar diameters, microvascular permeability, functional capillary density (FCD), number of rolling and sticking leukocytes were evaluated on ear microcirculation. Images of the sclerotherapy site were taken before and after the procedure.
Compared to placebo, MPFF treatment prevented the increase in venular diameter, preserved FCD (P < 0.001) and reduced the number of leaky sites (P < 0.001) and sticking leukocytes (P < 0.001). Imaging confirmed these effects on thrombosis and perivascular edema of the sclerosed vein, 14 days after procedure.
MPFF treatment limited the postsclerotherapy inflammation in surrounding microvascular network, suggesting that MPFF may prevent undesirable secondary effects of the procedure in this animal model. This study warrants further investigation for its use in clinical conditions.
评估微粉化纯化黄酮类成分（MPFF）治疗是否可通过将周围组织内的炎症反应降至最低，来减轻硬化疗法（一种常用于治疗静脉疾病表现的方法）的副作用。
22只雄性新西兰兔在硬化疗法前7天开始，连续21天经口灌胃给予微粉化纯化黄酮类成分（MPFF；300毫克/千克/天）或赋形剂（10%乳糖溶液）。硬化疗法包括在兔耳背静脉注射含5%油酸乙醇胺溶液。在硬化疗法前后，评估耳微循环的小静脉和小动脉直径、微血管通透性、功能性毛细血管密度（FCD）、滚动和黏附白细胞数量。在治疗前后拍摄硬化疗法部位的图像。
与安慰剂相比，MPFF治疗可防止小静脉直径增加，维持FCD（P<0.001），并减少渗漏部位数量（P<0.001）和黏附白细胞数量（P<0.001）。成像证实了在治疗后14天对硬化静脉血栓形成和血管周围水肿的这些影响。
MPFF治疗限制了硬化疗法后周围微血管网络的炎症，表明MPFF可能预防该动物模型中该治疗的不良继发效应。本研究值得进一步研究其在临床情况中的应用。
